6 hrs ago
Invitae raises $40 million to expand scope of genetic test
Genetic diagnostics company Invitae Corp. raised $40 million in a Series E round that included founder Randy Scott and his former company, Genomic Health Inc. The San Francisco company, which this year introduced its test that sequences more than 200 genes, said the cash will accelerate development of more tests for cancer, cardiology, neurology ... (more)
14 hrs ago
JPMorgan to host a conference
Check below for free stories on GEVA;LIN;AIR;ARX;BRKR;RLD;WPRT;FEIC;GOGO;MOD the last two weeks.
Mon Dec 09, 2013
Myriad Genetics Announces Cancer Research Collaboration With Janssen
Myriad Genetics, Inc. today announced that Janssen Research & Development, LLC, will use Myriad's BRAC Analysis test in connection with its Phase 3 clinical trial of Yondelis in the treatment of advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers .
Fri Dec 06, 2013
Myriad Genetics Inc Files (8-K) Disclosing Change in Directors or...
MYRIAD GENETICS INC FILES Disclosing Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Myriad Genetics: Is The Clerk Giving You A Buying Opportunity?
Of these, BRACAnalysis is the largest revenue contributor by far. It represented 74% of MYGN's revenues in the latest quarter, as can be seen below .
Thu Dec 05, 2013
Bio IT World
Myriad Still Holding Fast on BRCA Patents
Myriad Genetics has launched a new lawsuit over its ownership of genetic tests for BRCA mutations, this time against Laboratory Corporation of America , whose BRCA ssure test was launched commercially earlier this week.
Timeline of events: A brief history of what made news this year
Biomedical research in 2013 saw some dramatic developments, with unprecedented government action in the US ranging from the budget sequester in the spring to a dramatic government shutdown in autumn.
Harvard Business School
Encourage Breakthrough Health Care by Competing on Products Rather Than Patents
Like many people interested in the tangled connections between health care progress and intellectual property rights, I avidly followed the Myriad Genetics case , decided by the Supreme Court this June 13. In sum, molecular diagnostics maker Myriad sought "the exclusive right to isolate an individual's BRCA1 and BRCA2 genes," but the Court, wisely ... (more)
Wed Dec 04, 2013
The Motley Fool
The Nasdaq's 5 Most Hated Stocks
An ongoing monetary easing program from the Federal Reserve known as QE3, which has helped keep lending rates low and investors happy, continues to lead the charge higher.
Trader's Buzzers - Myriad Genetics, Inc. (NASDAQ:MYGN), Teva...
PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits - even in bear markets.
Tue Dec 03, 2013
Options with increasing implied volatility: Irm Mygn FRX Rax CNP
Stocks with call strike movement; MYGN JCP Myriad Genetics December 28 call option implied volatility increased 7% to 81, J.C. Penney March 12 call option implied volatility decreased 1% to 71 according to IVolatility.
Court Report -- December 01, 2013
Novartis Pharmaceuticals Corp. et al. v. Roxane Laboratories, Inc. 2:13-cv-07184; filed November 27, 2013 in the District Court of New Jersey Novartis Pharmaceuticals Corp. et al. v.
The Motley Fool
Sears Holdings, Home Depot Fall As Dow Slumps
Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis.
TrendingWallStreet.com Begins Volume Coverage on MYGN, FNMA, ABX, and ...
Whether it's a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.trendingwallstreet.com/ to get exclusive access to our free stock reports.
Mon Dec 02, 2013
Investors Purchase Large Volume of Put Options on Myriad Genetics
Myriad Genetics was the recipient of unusually large options trading activity on Monday.
Genetic testing firm Invitae counters Myriad patent infringement suit
Genetic testing startup Invitae Corp. fired back at Myriad Genetics Inc. , saying in a federal lawsuit filed last week that Myriad's patents around three cancer genes are invalid.
Investor's Business Daily
Myriad Genetics Sued On Gene Patents; Stock Falls
Invitae's move was a counterattack after Myriad named Invitae as a defendant in its own lawsuit, which Invitae said last week it would vigorously contest .
Myriad's invalidated patents spur LabCorp to offer competing breast cancer test
LabCorp has announced its version of a genetic test for mutations in the BRCA1 and BRCA2 genes that signal an increased risk of breast cancer.
Myriad Genetics hit by CMS concerns, patent suit
According the market chatter, Piper thinks the "'final' National Fee Schedule price of $1,438 for BRACAnalysis is likely an error ."
Sun Dec 01, 2013
The Huffington Post
Genetic Testing Should Adhere to Medical, Not Business, Ethics: FDA's ...
This week the Food and Drug Administration issued a warning letter to the direct-to-consumer genetic testing company 23andMe, demanding that it immediately stop marketing and selling its DNA testing service until it receives approval from the agency tasked with regulating medical tests and devices.